Octocog alfa

Key facts

Invented name
Advate
Active substance
octocog alfa
Therapeutic area
Haematology-Hemostaseology
Decision number
P/65/2010
PIP number
Octocog alfa
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Haemophilia A (congenital Factor VIII deficiency)
Route(s) of administration
Intravenous use
Contact for public enquiries
Applicant: Baxter AG
E-mail: juliana_brankova@baxter.com
Country: Austria
Phone: +43 1201002548
Fax: + 43 120100727
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating